Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
![]() |
BRCA1 mutations in a selected series of breast/ovarian cancer patientsGarvin, A M ; Spycher, M ; Häner, M ; Torhorst, J ; Müller, H ; Herrmann, R ; Rochlitz, C ; Weber, W ; Scott, R JJournal of medical genetics, 1996-09, Vol.33 (9), p.721-725 [Periódico revisado por pares]London: BMJ Publishing Group LtdTexto completo disponível |
2 |
Material Type: Artigo
|
![]() |
The status of p53 in the metastatic progression of colorectal cancerHeide, I ; Thiede, C ; Sonntag, T ; de Kant, E ; Neubauer, A ; Jonas, S ; Peter, F.J ; Neuhaus, P ; Herrmann, R ; Huhn, D ; Rochlitz, C.FEuropean journal of cancer (1990), 1997-07, Vol.33 (8), p.1314-1322 [Periódico revisado por pares]Oxford: Elsevier LtdTexto completo disponível |
3 |
Material Type: Artigo
|
![]() |
bcl-2 expression is reciprocal to p53 and c-myc expression in metastatic human colorectal cancerPopescu, R.A ; Lohri, A ; de Kant, E ; Thiede, C ; Reuter, J ; Herrmann, R ; Rochlitz, C.FEuropean journal of cancer (1990), 1998-07, Vol.34 (8), p.1268-1273 [Periódico revisado por pares]Oxford: Elsevier LtdTexto completo disponível |
4 |
Material Type: Artigo
|
![]() |
Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumorsRochlitz, C ; Jantscheff, P ; Bongartz, G ; Dietrich, P Y ; Quiquerez, A L ; Schatz, C ; Mehtali, M ; Courtney, M ; Tartour, E ; Dorval, T ; Fridman, W H ; Herrmann, RCancer gene therapy, 1999-05, Vol.6 (3), p.271-281 [Periódico revisado por pares]England: Nature Publishing GroupTexto completo disponível |
5 |
Material Type: Artigo
|
![]() |
Cancer gene and immunotherapy : recent developmentsJANTSCHEFF, P ; HERRMANN, R ; ROCHLITZ, CCancer Immunology, Immunotherapy, 1999-07, Vol.16 (2), p.78-85 [Periódico revisado por pares]Heidelberg: SpringerTexto completo disponível |
6 |
Material Type: Artigo
|
![]() |
P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patientsBoulay, J L ; Perruchoud, A P ; Reuter, J ; Bolliger, C ; Herrmann, R ; Rochlitz, CCancer gene therapy, 2000-09, Vol.7 (9), p.1215-1219 [Periódico revisado por pares]England: Nature Publishing GroupTexto completo disponível |
7 |
Material Type: Artigo
|
![]() |
Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findingsTARTOUR, E ; MEHTALI, M ; HERRMANN, R ; POUILLART, P ; FRIDMAN, W. H ; DORVAL, T ; SASTRE-GARAU, X ; JOYEUX, I ; MATHIOT, C ; PLEAU, J. M ; SQUIBAN, P ; ROCHLITZ, C ; COURTNEY, M ; JANTSCHEFF, PBritish Journal of Cancer, 2000-12, Vol.83 (11), p.1454-1461 [Periódico revisado por pares]Basingstoke: Nature Publishing GroupTexto completo disponível |
8 |
Material Type: Artigo
|
![]() |
Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancerMAMOT, C ; MILD, G ; REUTER, J ; LAFFER, U ; METZGER, U ; TERRACCIANO, L ; BOULAY, J-L ; HERRMANN, R ; ROCHLITZ, CBritish journal of cancer, 2003-02, Vol.88 (3), p.420-423 [Periódico revisado por pares]Basingstoke: Nature Publishing GroupTexto completo disponível |
9 |
Material Type: Artigo
|
![]() |
SMAD7 is a prognostic marker in patients with colorectal cancerBoulay, Jean‐Louis ; Mild, Gabriele ; Lowy, Adam ; Reuter, Juergen ; Lagrange, Magali ; Terracciano, Luigi ; Laffer, Urban ; Herrmann, Richard ; Rochlitz, ChristophInternational journal of cancer, 2003-04, Vol.104 (4), p.446-449 [Periódico revisado por pares]New York: Wiley Subscription Services, Inc., A Wiley CompanyTexto completo disponível |
10 |
Material Type: Artigo
|
![]() |
Toxic Encephalopathy Induced by CapecitabineNiemann, B. ; Rochlitz, C. ; Herrmann, R. ; Pless, M.Oncology, 2004-01, Vol.66 (4), p.331-335 [Periódico revisado por pares]Basel, Switzerland: KargerTexto completo disponível |